Your AI-Trained Oncology Knowledge Connection!

Exploring Biliary Tract Cancer: Top Takeaways From ASCO GI 2025 : Episode 12

Opinion

Video

March 26, 2025

Future Perspectives and Unmet Needs in HER2-Positive Advanced BTC Treatment

Author(s):

Panelists discuss how significant challenges remain in HER2-positive biliary tract cancer (BTC), including optimizing sequencing of targeted therapies, addressing resistance mechanisms, improving biomarker testing accessibility, and developing strategies for brain metastases.

EP: 1.Guiding Patients Through Advanced BTC Prognosis and Expectations

EP: 2.The Importance of Early Biomarker Testing in Managing Advanced BTC

EP: 3.Biomarker Testing in BTC: Approaches and Practices Across Academic and Community Clinicians

EP: 4.Expert Insights: Challenges With ctDNA Testing in BTC

EP: 5.Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials

EP: 6.Applying Data to Clinical Practice: Immunotherapy in the First-Line Treatment Setting in Advanced BTC

EP: 7.Understanding HER2 Testing in BTC: Detection and Clinical Approaches

EP: 8.Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

EP: 9.New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study

EP: 10.Expert Perspectives in HER2-Positive BTC: Trastuzumab With Pertuzumab or Tucatinib From MyPathway and SGNTUC-019 Trials

EP: 11.Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC

Now Viewing

EP: 12.Future Perspectives and Unmet Needs in HER2-Positive Advanced BTC Treatment

EP: 13.Key Takeaways From ASCO GI 2025: Exciting Updates on BTC

Video content above is prompted by the following:

What are some remaining unmet needs for those with HER2, advanced BTC?

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

May 14th 2025 - May 15th 2026

online-activity

Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

May 13th 2025 - Jun 18th 2025

online-activity

Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity

Latest Conference Coverage

Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer

Emiltatug Ledadotin Shows Early Clinical Activity and Safety in Advanced/Metastatic TNBC

Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer

Adjuvant Pertuzumab Plus Trastuzumab and Chemotherapy Leads to OS Benefit in Early-Stage HER2+ Breast Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Future Perspectives and Unmet Needs in HER2-Positive Advanced BTC Treatment

EP: 1.Guiding Patients Through Advanced BTC Prognosis and Expectations

EP: 2.The Importance of Early Biomarker Testing in Managing Advanced BTC

EP: 3.Biomarker Testing in BTC: Approaches and Practices Across Academic and Community Clinicians

EP: 4.Expert Insights: Challenges With ctDNA Testing in BTC

EP: 5.Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials

EP: 6.Applying Data to Clinical Practice: Immunotherapy in the First-Line Treatment Setting in Advanced BTC

EP: 7.Understanding HER2 Testing in BTC: Detection and Clinical Approaches

EP: 8.Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

EP: 9.New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study

EP: 10.Expert Perspectives in HER2-Positive BTC: Trastuzumab With Pertuzumab or Tucatinib From MyPathway and SGNTUC-019 Trials

EP: 11.Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC

EP: 12.Future Perspectives and Unmet Needs in HER2-Positive Advanced BTC Treatment

EP: 13.Key Takeaways From ASCO GI 2025: Exciting Updates on BTC

Newsletter

Latest CME

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Latest Conference Coverage